What is the Purpose of this Study?
This study focuses on people who have advanced non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma, or other solid tumor with a specific KRAS mutation (change in the KRAS gene that plays a part in cancer development). The purpose of the study is to find the best dose of an experimental drug called BBO-11818 when used alone and in combination with other standard-of-care treatments. Specifically, the study aims to determine the effects of BBO-11818 on participants with advanced solid tumors when given alone or given in combination with other cancer treatments, including pembrolizumab, pemetrexed, cisplatin, carboplatin, and cetuximab. While pembrolizumab, pemetrexed, cisplatin, carboplatin, cetuximab, FOLFOX, NALIRIFOX, gemcitabine, and nab-paclitaxel are approved by the U.S. Food and Drug Administration (FDA) individually, the combination of BBO-11818 with these treatments is considered experimental.
Eligibility
- * Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation
- * Measurable disease by RECIST v1.1
- * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
Where can I participate?
CS Cancer at The Angeles Clinic and Research Institute : Marquis Keene, Saba Mukarram
More about this Clinical Trial
What is the full name of this clinical trial?
TBBO11818-101: A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects with Advanced KRAS Mutant Cancers